Discontinued — last reported Q1 '26
Delstrigo — Sales
Merck & Co. Delstrigo — Sales decreased by 52.2% to $75.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 44.0%, from $134.00M to $75.00M. Over 3 years (FY 2022 to FY 2025), Delstrigo — Sales shows an upward trend with a 26.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase in sales indicates strong market penetration, successful clinical adoption, or effective commercial execution for this specific therapy. A decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total annual revenue generated from the sale of a specific pharmaceutical product line within...
Peer comparison
Comparable to revenue metrics for specific branded pharmaceutical products or therapeutic franchises at other major biopharmaceutical companies.
mrk_segment_delstrigo_salesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $75.25M | $75.25M | $75.25M | $75.25M | $88.00M | $100.00M | $107.00M | $107.00M | $112.00M | $119.00M | $130.00M | $137.00M | $134.00M | $167.00M | $154.00M | $157.00M | $75.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +16.9% | +13.6% | +7.0% | +0.0% | +4.7% | +6.3% | +9.2% | +5.4% | -2.2% | +24.6% | -7.8% | +1.9% | -52.2% |
| YoY Change | — | — | — | — | +16.9% | +32.9% | +42.2% | +42.2% | +27.3% | +19.0% | +21.5% | +28.0% | +19.6% | +40.3% | +18.5% | +14.6% | -44.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s delstrigo — sales?
- Merck & Co. (MRK) reported delstrigo — sales of $75.00M in Q1 2026.
- How has Merck & Co.'s delstrigo — sales changed year-over-year?
- Merck & Co.'s delstrigo — sales decreased by 44.0% year-over-year, from $134.00M to $75.00M.
- What is the long-term trend for Merck & Co.'s delstrigo — sales?
- Over 3 years (2022 to 2025), Merck & Co.'s delstrigo — sales has grown at a 26.7% compound annual growth rate (CAGR), from $301.00M to $612.00M.
- What does delstrigo — sales mean?
- The total annual revenue generated by the sales of the Delstrigo pharmaceutical product.